Sarepta Therapeutics, Inc. SRPT EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Sarepta Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed August 7, 2024, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s EBITDA margin?
- Sarepta Therapeutics, Inc. (SRPT) reported EBITDA margin of -46.5% in Q2 2023.
- How has Sarepta Therapeutics, Inc.'s EBITDA margin changed year-over-year?
- Sarepta Therapeutics, Inc.'s EBITDA margin increased by 2.2% year-over-year, from -47.5% to -46.5%.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s EBITDA margin?
- Over 2 years (2020 to 2022), Sarepta Therapeutics, Inc.'s EBITDA margin has grown at a -27.0% compound annual growth rate (CAGR), from -99.5% to -53%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.